What is Mabylon?
Mabylon AG is a Swiss biotechnology firm at the forefront of developing human-derived antibody therapies. The company's pipeline is focused on addressing severe allergies, neurodegenerative diseases, and inflammatory conditions. With drug candidates progressing through clinical trials and established collaborations with major industry players, Mabylon is positioning itself as a significant innovator in biopharmaceuticals.
How much funding has Mabylon raised?
Mabylon has raised a total of $37.1M across 1 funding round:
Other Financing Round
$37.1M
Other Financing Round (2025): $37.1M, investors not publicly disclosed
What's next for Mabylon?
The substantial enterprise-level funding Mabylon AG has attracted signals a critical phase of scaling and market penetration. This capital infusion is expected to accelerate the clinical development of its novel antibody therapies and potentially fund strategic partnerships or acquisitions. The company's focus on severe unmet medical needs, coupled with its robust scientific foundation, suggests a trajectory towards significant market impact and potential future rounds of financing to support commercialization efforts.
See full Mabylon company page
